NCT00390884View on ClinicalTrials.gov

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

PHASE4CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

September 30, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Virus Vaccine, Fluzone®

0.25 mL, Intramuscular

BIOLOGICAL

Influenza Virus Vaccine, Fluzone®

0.25 mL, Intramuscular

Trial Locations (5)

84041

Layton

84062

Pleasant Grove

84095

South Jordan

84107

Salt Lake City

84604

Provo

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00390884 - Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation. | Biotech Hunter | Biotech Hunter